“The Renal Insufficiency And Cardiovascular Events (RIACE)” Italian Multicenter Study - Prevalenza e ruolo predittivo della riduzione del filtrato glomerulare stimato (eGFR) sul rischio cardiovascolare nel diabete tipo 2: studio multicentrico italiano
Coordinatore e collaboratori
Coordinatore: Giuseppe Pugliese
Segretario scientifico: Giuseppe Penno
Comitato scientifico: Anna Solini, Enzo Bonora, Emanuela Orsi, Roberto Trevisan, Luigi Laviola, Antonio Nicolucci
Centri partecipanti
1. Azienda Ospedaliera Sant'Andrea, Roma (Centro Coordinatore): Giuseppe Pugliese, Paola Simonelli, Andrea Negro, Laura Salvi, Alessandra Bazuro, Aurora Frasheri.
2. Ospedale Le Molinette, Torino: Paolo Cavallo-Perin, Gabriella Gruden, Bartolomeo Lorenzati.
3. Ospedale San Luigi Gonzaga, Orbassano: Mariella Trovati, Giovanni Anfossi, Franco Cavalot, Massimo Chirio.
4. Ospedale San Raffaele, Milano: Giampaolo Zerbini, Valentina Martina.
5. IRCCS “Cà Granda – Ospedale Maggiore Policlinico”, Milano: Emanuela Orsi, Laura Montefusco.
6. Ospedale San Paolo, Milano: Antonio Pontiroli, Marco Laneri.
7. Ospedale San Giuseppe, Milano: Maura Arosio, Alessia Dolci.
8. Ospedali Riuniti, Bergamo: Roberto Trevisan, Anna Corsi.
9. Ospedale Maggiore, Verona: Enzo Bonora, Giacomo Zoppini.
10. Policlinico Universitario, Padova: Angelo Avogaro, Monica Vedovato, Elisa Pagnin.
11. Ospedale Cisanello, Azienda Ospedaliero-Universitaria Pisana, Pisa: Giuseppe Penno, Laura Pucci, Daniela Lucchesi, Eleonora Russo, Monia Garofolo.
12. Ospedale Santa Chiara, Azienda Ospedaliero-Universitaria Pisana, Pisa: Anna Solini.
13. Ospedale Le Scotte, Siena: Francesco Dotta, Cecilia Fondelli, Laura Nigi.
14. Policlinico Umberto I, Roma: Susanna Morano, Alessandra Gatti.
15. Ospedale S. Maria Goretti, Latina: Raffaella Buzzetti.
16. Ospedali Riuniti, Foggia: Mauro Cignarelli, Olga Lamacchia, Sabina Pinnelli.
17. Policlinico Universitario, Bari: Francesco Giorgino, Luigi Laviola, Sebastio Perrini.
18. Policlinico Mater Domini, Catanzaro: Giorgio Sesti, Francesco Andreozzi.
19. Policlinico Monserrato, Cagliari: Marco Giorgio Baroni, Giuseppina Frau.
Finanziamenti
Il progetto è stato finanziato dalla SID con € 125.000 in 3 tranche.
Ulteriori finanziamenti, pari a € 115.000, sono stati ottenuti da:
- Takeda: € 22.000;
- Boehringer: € 22.000;
- Chiesi: € 20.000;
- Eli Lilly: € 50.000, di cui manca l’ultima tranche di € 10.000;
- Fondazione DEM: € 1.000.
Abstract
Studi recenti hanno indicato come, nella popolazione non diabetica, la riduzione del filtrato glomerulare (GFR) sia un forte predittore di morbilità e mortalità cardiovascolare, indipendentemente dai fattori di rischio cardiovascolari tradizionali. I soggetti con diabete mellito di tipo 2 sono caratterizzati da un eccesso di morbilità e mortalità cardiovascolare rispetto alla popolazione generale. Quindi dal punto di vista clinico è importante individuare fattori in grado di predire gli eventi cardiovascolari in tali pazienti. Un importante predittore è rappresentato da valori elevati di albumineria; infatti nei pazienti diabetici di tipo 2 macroalbuminurici il rischio individuale di dialisi e relativamente basso, mentre il tasso di mortalità cardiovascolare è elevato. Non è invece noto al momento se la stima del GFR fornisca informazioni aggiuntive nei diabetici e se l’eventuale ruolo predittivo sia indipendente da quello dell’albuminuria. Il presente progetto si propone di stimare, in una coorte multicentrica di 15.000 diabetici, rappresentativa della popolazione diabetica in carico presso le strutture diabetologiche italiane, i seguenti dati:
1. La prevalenza della riduzione del GFR e la sua associazione con l’albuminuria ed i fattori di rischio tradizionali (studio trasversale);
2. Il suo ruolo predittivo indipendente su morbilità e mortalità cardiovascolare in un follow-up di 5 anni (studio longitudinale).
Inoltre, il database potrà essere utilizzato in futuro per studi riguardanti aspetti genetici o fisiopatologici o per studi di intervento, da eseguire su un sottogruppo randomizzato di pazienti, in base a proposte dei singol ricercatori e centri coinvolti. I risultati dello studio saranno oggetto di pubblicazione scientifica a cura del comitato di coordinamento del Gruppo di Studio, in rappresentazione della SID.
Stato dello studio
Studio basale: 2007-2008 (completato con l’arruolamento di 15773 pazienti)
Follow-up: 2012-2018 (attualmente in corso)
Protocollo
Scopi dello studio
L’indagine si propone di stimare, in un’ampia coorte clinica multicentrica di soggetti con diabete di tipo 2:
- la prevalenza della riduzione dell’eGFR e la sua associazione con i fattori di rischio cardiovascolari noti e con l’albunimuria;
- il ruolo predittivo dell’eGFR su morbilità e mortalità cardiovascolare in un follow-up di 5 anni, indipendentemente dai fattori di rischio cardiovascolari noti e dall’albunimuria;
- l’incidenza di micro e macroalbuminuria e riduzione del GFR in un follow-up di 5 anni.
Durata dello studio
7 anni (complessiva)
Fasi dello studio
Lo studio si compone di due fasi:
- Studio trasversale (al tempo 0);
- Studio longitudinale (a 5 anni di distanza).
Pazienti
Lo studio prevede il reclutamento di pazienti diabetici di tipo 2 consecutivamente afferenti ai centri partecipanti distribuiti su tutto il territorio nazionale.
Raccolta dei dati
Il progetto prevede la raccolta, al tempo 0 (studio trasversale) e dopo 5 anni di follow-up (studio longitudinale), di:
Dati anamnestici
- abitudini di vita (fumo, attività fisica);
- familiarità (per diabete, dislipidemie, ipertensione e malattie cardiovascolari precoci);
- diabete e compenso glicemico pregresso (media <4 HbA1c eseguite negli ultimi 2 anni);
- dislipidemia, ipertensione e relative terapie;
- trattamento antiaggregante e anticoagulante;
- comorbidità (neoplasie, distiroidismi, BPCO, epatopatia cronica, altre malattie renali);
- eventi cardiovascolari maggiori (infarto miocardico, ictus, ulcera/gangrena/amputazione e rivascolarizzazioni coronarica, carotidea ed arti inferiori) e ricovero per scompenso cardiaco (soltanto nello studio longitudinale);
- eventuale morte e relative cause (soltanto nello studio longitudinale).
Dati clinici
- peso, altezza e circonferenza vita (facoltativa);
- pressione arteriosa sistolica e diastolica.
Dati laboratoristici
- HbA1c;
- colesterolo totale e HDL, trigliceridi;
- creatininemia e albumin excretion rate (AER) o albuminuria e creatininuria su urine spot.
Dati strumentali
- fundus oculi.
Ad ogni centro viene data libertà di ricavare le informazioni tramite archivio cartaceo o computerizzato, qualora correntemente aggiornato per tutte le informazioni necessarie allo studio, oppure direttamente tramite l’intervista o l’esame clinico del paziente.
Le indagini di laboratorio e strumentali vengono effettuate nelle diverse strutture diabetologiche. Al fine di garantire la comparabilità dei dati, i risultati dell’HbA1c e dell’albuminuria vengono standardizzati.
Ogni centro deve mantenere traccia nel proprio archivio degli eventi cardiovascolari maggiori (infarto miocardico, ictus, ulcera/gangrena/amputazione e rivascolarizzazioni coronarica, carotidea ed arti inferiori) intercorsi in un periodo di follow-up di 5 anni e della data di diagnosi dell’evento.
In caso di decesso, debbono esserne riportate le cause, ricavate dallo SDO o dal certificato di morte.
Inserimento dei dati
I dati vengono raccolti attraverso la compilazione di una scheda su un database online al quale è possibile accedere via internet grazie ad un software installato su un server dedicato. La scheda è dotata di soluzioni informatiche atte a facilitare e guidare l’operatore nella sua compilazione
Il software presenta le seguenti caratteristiche:
- creazione del sito web;
- creazione del database nefropatia (scheda raccolta dati);
- creazione del database dei centri;
- creazione del database del personale che inserisce i dati per la gestione dei privilegi di accesso;
- controlli automatici del corretto inserimento dei dati;
- analisi dei dati su filemaker, da cui è semplice il trasferimento al software per l'analisi statistica.
Il server presenta le seguenti caratteristiche:
- accessibilità a tutti i centri partecipanti limitatamente ai dati del singolo centro;
- accessibilità nel complesso (intero database) a tutti i componenti del comitato di coordinamento.
Analisi dei dati
Per ciascun paziente verranno calcolati automaticamente: età (anni); BMI (kg/m2); durata diabete (anni); HbA1c standardizzata (%); HbA1c pregressa media standardizzata (%); circonferenza vita stimata (cm) da BMI in caso di non determinazione; colesterolo LDL e non-HDL (mg/dl); PA media (mmHg); eGFR secondo la formula dello studio MDRD modificata e la formula CKD-EPI (ml/min/1.73 m2); AER stimata (mg/die) da rapporto A/C in caso di raccolta spot; età di morte (anni).
I pz. vengono suddivisi in 3 classi riguardo ai valori di albuminuria:
normoalbuminurici: AER <20 μg/min - ACR <30 μg/mg;
microalbuminurici: AER 20-199 μg/min - ACR 30-299 μg/mg;
macroalbuminurici: AER >200 μg/min - ACR >300 μg/mg;
I pz. vengono suddivisi in 5 classi (la classe 3 viene ulteriormente suddivisa in 2 sottoclassi) riguardo ai livelli di eGFR (formula dello studio MDRD modificata o formula CKD-EPI):
1. >90 ml/min/1,73 m2;
2. 60-89 ml/min/1,73 m2;
3a. 45-59 ml/min/1,73 m2;
3b. 30-44 ml/min/1,73 m2;
4. 15-29 ml/min/1,73 m2;
5. <15 ml/min/1,73 m2.
I pz. vengono definiti normopeso, soprappeso o obesi in base ai livelli di BMI: normopeso = <25 kg/m2; soprappeso = >25 - <30 kg/m2; obesità I grado = >30 - <35 kg/m2; obesità II grado = >35 - <40 kg/m2; obesità III grado = >40 kg/m2.
I pazienti vengono definiti affetti da obesità centrale se circonferenza vita > 102 cm (M) o 88 cm (F).
I pz. vengono definiti dislipidemici se livelli di trigliceridi, colesterolo HDL o colesterolo LDL anormali o in trattamento ipolipemizzante. I livelli di trigliceridi vengono definiti elevati se >150 mg/dl; i livelli di colesterolo HDL vengono definiti ridotti se <40 mg/dl (M) o <50 mg/dl (F); i livelli di colesterolo non-HDL vengono definiti elevati se >130 mg/dl; i livelli di colesterolo LDL vengono definiti elevati se >100 mg/dl.
I pz. vengono definiti ipertesi se livelli pressori >130/80 mmHg o in trattamento ipotensivo.
L’analisi statistica viene eseguita presso l’Istituto Mario Negri Sud dal Dr. Antonio Nicolucci.
Stato di avanzamento dello studio
1. Studio trasversale: completato negli anni 2007-2008 con l’arruolamento di 15.773 pazienti.
2. Studio longitudinale. Completato a dicembre 2014, attualmente sono in corso la verifica dei dati raccolti e la ricerca di informazioni su pazienti mancanti.
Link
http://www.renediabete.it/
http://clinicaltrials.gov/ct2/show/NCT00715481
Pubblicazioni
Lista Riace Papers (pubblicati)
![]() |
Reproducibility of albuminuria in type 2 diabetic subjects. Findings from the Renal Insufficiency And Cardiovascular Events (RIACE) study. |
![]() |
The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation provides a better definition of cardiovascular burden associated with CKD than the Modification of Diet in Renal Disease (MDRD) Study formula in subjects with type 2 diabetes. |
![]() |
Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. |
![]() |
Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. |
![]() |
High prevalence of advanced retinopathy in patients with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. |
![]() |
Rate and determinants of association between advanced retinopathy and chronic kidney disease in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study. |
![]() |
HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study. |
![]() |
Gender differences in cardiovascular disease risk factors, treatments and complications in patients with type 2 diabetes: the RIACE Italian multicentre study. |
![]() |
Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. |
![]() |
Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study. |
![]() |
Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. |
![]() |
Chronic kidney disease in type 2 diabetes: Lessons from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. |
![]() |
Resistant hypertension in patients with type 2 diabetes: clinical correlates and association with complications. |
![]() |
Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. |
![]() |
Independent correlates of urinary albumin excretion within the normoalbuminuric range in patients with type 2 diabetes: The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. |
Lista Riace Papers (pubblicati)
|
Defining the contribution of chronic kidney disease to all‑causemortality in patients with type 2 diabetes: the Renal InsufficiencyAnd Cardiovascular Events (RIACE) Italian Multicenter Study |
|
|
Haemoglobin A1c variability is a strong, independent predictorof all-cause mortality in patients with type 2 diabetes |
Presentazioni a Congressi
![]() |
The Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study: baseline data. |
![]() |
Complicanze micro e macrovascolari nei pazienti italiani con diabete di tipo 2: risultati basali dello studio RIACE. |
|
L’insufficienza renale normoalbuminurica è la forma più frequente di malattia renale cronica nei diabetici di tipo 2 in Italia. |
|
|
Caratteristiche cliniche della popolazione diabetica di tipo 2 in Italia: risultati basali dello studio RIACE. |
|
![]() |
Normoalbuminuric renal insufficiency is the predominant clinical presentation of kidney disease in patients with type 2 diabetes in Italy. |
![]() |
Cardiovascular risk factors and micro- and macrovascular complications in patients with type 2 diabetes in Italy. G. Pugliese, A. Solini, E. Bonora, E. Orsi, G. Zerbini, C. Fondelli, S. Morano, M. Cignarelli, L. Laviola, F. Cavalot, G. Gruden, R. Trevisan, M. Vedovato, A. Nicolucci, G. Penno. 46th Annual EASD Meeting, Stockholm, 20-24 September 2010 |
![]() |
Association of normoalbuminuric renal impairment with cardiovascular disease. G. Penno, A. Solini, E. Bonora, C. Fondelli, E. Orsi, G. Zerbini, R. Trevisan, M. Vedovato, G. Gruden, F. Cavalot, O. Lamacchia, L. Laviola, S. Morano, G. Pugliese, for the RIACE Study Group. 24th European Diabetic Nephropathy Study Group Meeting, Lubljana, 19-21 May, 2011 |
![]() |
Association of normoalbuminuric renal impairment with cardiovascular disease. G. Pugliese, G. Penno, E. Bonora, E. Orsi, G. Zerbini, C. Fondelli, G. Gruden, F. Cavalot, M. Cignarelli, L. Laviola, S. Morano, M. Vedovato, R. Trevisan, A. Nicolucci, A. Solini. 47th Annual EASD Meeting, Lisbon, 12-16 September 2010 |
![]() |
Concordance between nephropathy and retinopathy in patients with type 2 diabetes: the RIACE Study. |
|
Age, kidney function, and treatment for type 2 diabetes: the RIACE Study. |
|
![]() |
Differenze di genere nel controllo dei fattori di riscvhio cardiovascolare nei pazienti con diabete di tipo 2: lo studio RIACE. |
|
Attuale prevalenza e correlati della retinopatia in pazienti con diabete di tipo 2: lo studio RIACE. |
|
|
Età, funzione renale e terapia nel diabete tipo 2: lo studio RIACE. |
|
![]() |
Rate and determinants of association between retinopathy and nephropathy in patients with type 2 diabetes in Italy. |
![]() |
Resistant hypertension in subjects with type 2 diabetes: clinical correlates and association with renal, retinal and cardiovascular complications. |
|
Reclassification of patients with type 2 diabetes using the alternate system for chronic kidney disease based on both albuminuria and estimated glomerular filtration rate. |
|
|
Association of hypertriglyceridemia with renal, retinal and cardiovascular complications in subjects with type 2 diabetes. |
|
![]() |
Resistant hypertension: clinical correlates and association with complications in subjects with type 2 diabetes. |
|
Association of hypertriglyceridemia with complications in subjects with type 2 diabetes. |
|
![]() |
Prevalence of the metabolic syndrome and association with chronic kidney disease in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. |
|
Re-evaluation of patients with type 2 diabetes using the eight Joint National Committee cut-offs for blood pressure: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. |
|
|
Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. |
|
|
RUTH OSTERBY LECTURE 2014 |
|
![]() |
Prevalenza di soggetti con diabete di tipo 2 che raggiungono target personalizzati di HbA1c. |
|
Determinanti dell’escrezione urinaria di albumina nel range di normalità in pazienti con diabete tipo 2. |
|
|
Rivalutazione dei target pressori in pazienti con diabete di tipo 2 secondo i criteri del Joint National Committee 8. |
|
![]() |
Achievement of personalized HbA1c targets in patients with type 2 diabetes from the RIACE cohort. |
|
Re-evaluation of patients with type 2 diabetes from the RIACE cohort using the 8th Joint National Committee cut-offs for blood pressure. |
|
|
Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. |
Citazioni
|
Normoalbuminuric diabetic kidney disease in the U.S. population. |
|
|
Thresholds of various glycemic measures for diagnosing diabetes based on prevalence of retinopathy in community-dwelling Japanese subjects: the Hisayama Study |
|
|
GFR estimation: from physiology to public health. |
|
|
Sex differences in type 2 diabetes: focus on disease course and outcomes. |
|
|
HbA1c Variability and the Risk of Renal Status Progression in Diabetes Mellitus: A Meta-Analysis. |
|
|
Optimal therapy of type 2 diabetes: a controversial challenge. |
|
|
Chronic kidney disease and support provided by home care services: a systematic review. |
|
|
Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. |
|
|
Cardiovascular risk stratification and management in pre-diabetes. |
|
|
Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes. |
|
|
A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure. |
|
|
Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. |
|
|
Letter: a1c variability can predict coronary artery disease in patients with type 2 diabetes with mean a1c level greater than 7 (Endocrinol Metab 2013; 28: 125-32, Eun Ju Lee et al.). |
|
|
Response: a1c variability can predict coronary artery disease in patients with type 2 diabetes with mean a1c level greater than 7 (Endocrinol Metab 2013; 28: 125-32, Eun Ju Lee et al.). |
|
|
Differences in the Cardiometabolic Control in Type 2 Diabetes according to Gender and the Presence of Cardiovascular Disease: Results from the eControl Study. |
|
|
Diabetic retinopathy and renal function in Chinese type 2 diabetic patients. |
|
|
Is chronic kidney disease associated with diabetic retinopathy in Asian adults? |
|
|
Cardiovascular risk factors and complications associated with albuminuria and impaired renal function in insulin-treated diabetes. |
|
|
The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. |
|
|
Glycated hemoglobin variability: A potential new risk marker for diabetes complications? |
|
|
Kidney and eye diseases: common risk factors, etiological mechanisms, and pathways.
|
|
|
Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes.
|
|
|
Correlates of muscle strength in diabetes: The study on the assessment of determinants of muscle and bone strength abnormalities in diabetes (SAMBA).
|
|
|
The ideal blood pressure target to prevent cardiovascular disease in type 2 diabetes: a neutral viewpoint.
|
|
|
Vascular endothelial growth factor in anterior chamber liquid patients with diabetic retinopathy, cataract and neovascular glaucoma.
|
|
|
Fluctuation between fasting and 2-H postload glucose state is associated with chronic kidney disease in previously diagnosed type 2 diabetes patients with HbA1c ≥ 7%.
|
|
|
HbA1c variability as an independent risk factor for diabetic retinopathy in type 1 diabetes: a German/Austrian multicenter analysis on 35,891 patients.
|
|
|
Fluctuation between fasting and 2-H postload glucose state is associated with glomerular hyperfiltration in newly diagnosed diabetes patients with HbA1c < 7%.
|
|
|
The purinergic 2X7 receptor participates in renal inflammation and injury induced by high-fat diet: possible role of NLRP3 inflammasome activation.
|
|
|
How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study.
|
|
|
Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin.
|
|
|
Angiosome-targeted revascularisation in diabetic foot ulcers.
|
|
|
Significance of estimating the glomerular filtration rate for the management of hypertension in type 2 diabetes with microalbuminuria.
|
|
|
Four-year incidence of diabetic retinopathy in a Spanish cohort: the MADIABETES study.
|
|
|
Association between accelerometer-assessed physical activity and objectively measured hearing sensitivity among U.S. adults with diabetes.
|
|
|
Improving quality of care in people with Type 2 diabetes through the Associazione Medici Diabetologi-annals initiative: a long-term cost-effectiveness analysis.
|
|
|
Both High and Low HbA1c Predict Incident Heart Failure in Type 2 Diabetes Mellitus.
|
|
|
Psychological aspects of diabetes care: Effecting behavioral change in patients. World J Diabetes. 2014; 5: 796-808
|
|
|
Psychological aspects of diabetes care: Effecting behavioral change in patients. World J Diabetes. 2014; 5: 796-808
|
|
|
Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes.
|
|
|
Evaluating self-management behaviors of diabetic patients in a telehealthcare program: longitudinal study over 18 months.
|
|
|
Impact of chronic kidney disease on the prevalence of cardiovascular disease in patients with type 2 diabetes in Spain: PERCEDIME2 study.
|
|
|
Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes.
|
|
|
Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives.
|
|
|
Sex disparities in the quality of diabetes care: biological and cultural factors may play a different role for different outcomes: a cross-sectional observational study from the AMD Annals initiative.
|
|
|
Prioritization of patient-related factors according to renal function in antidiabetic drug selection: the REDIM Project.
|
|
|
Diabetes mellitus and kidney disease in the elderly.
|
|
|
Comment on Zhang et Al. Second-line agents for glycemic control for type 2 diabetes: are newer agents better? Diabetes Care 2014;37:1338-1345.
|
|
|
Diabetes Mellitus, Physical Activity, and Longevity Between the Ages of 70 and 90.
|
|
|
Lipid and non-lipid cardiovascular risk factors in postmenopausal type 2 diabetic women with and without coronary heart disease.
|
|
|
Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum.
|
|
|
'Progressive diabetic nephropathy. How useful is microalbuminuria?: contra'.
|
|
|
Diabetes and hypertension: the bad companions.
|
|
|
Plasminogen activator inhibitor-1 is associated with renal dysfunction independent of BMI and serum lipid levels in patients with type 2 diabetes.
|
|
|
Epidemiology of diabetic kidney disease.
|
|
|
Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study.
|
|
|
An increase in perfusion pressure and activation of the renin-angiotensin system in the pathogenesis of hypertension and injury: strain vessels and the cerebrovascular-renal connection. Hypertens Res. 2012; 35: 972-974
|
|
|
An increase in perfusion pressure and activation of the renin-angiotensin system in the pathogenesis of hypertension and injury: strain vessels and the cerebrovascular-renal connection. Hypertens Res. 2012; 35: 972-974
|
|
|
Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature.
|
|
|
Blood pressure variability: a new target to slow the progression of vascular damage in type 2 diabetes?
|
|
|
Silent diabetic nephropathy.
|
|
|
Normoalbuminuric renal impairment and all-cause mortality in type 2 diabetes mellitus.
|
|
|
The changing landscape of diabetic kidney disease: new reflections on phenotype, classification, and disease progression to influence future investigative studies and therapeutic trials.
|
|
|
Kidney lesions in diabetic patients with normoalbuminuric renal insufficiency.
|
|
|
The synergistic relationship between estimated GFR and microalbuminuria in predicting long-term progression to ESRD or death in patients with diabetes: results from the Kidney Early Evaluation Program (KEEP).
|
|
|
Urine haptoglobin levels predict early renal functional decline in patients with type 2 diabetes.
|
|
|
Non-albuminuric renal disease among subjects with advanced stages of chronic kidney failure related to type 2 diabetes mellitus.
|
|
|
The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patients.
|
|
|
Active ingredients of traditional Chinese medicine in the treatment of diabetes and diabetic complications.
|
|
|
Ongoing treatment with renin-angiotensin-aldosterone-blocking agents does not predict normoalbuminuric renal impairment in a general type 2 diabetes population.
|
|
|
Chronic kidney disease in the type 2 diabetic patients: prevalence and associated variables in a random sample of 2642 patients of a Mediterranean area.
|
|
|
Inconsistency in albuminuria predictors in type 2 diabetes: a comparison between neural network and conditional logistic regression.
|
|
|
Gender difference in albuminuria and ischemic heart disease in type 2 diabetes.
|
|
|
Concomitant renal insufficiency and diabetes mellitus as prognostic factors for acute myocardial infarction.
|
|
|
Microalbuminuria in HIV disease.
|
|
|
Cardiac autonomic neuropathy predicts renal function decline in patients with type 2 diabetes: a cohort study.
|
|
|
Albuminuria prevalence in first morning void compared with previous random urine from adults in the National Health and Nutrition Examination Survey, 2009-2010.
|
|
|
Obstructive sleep apnea and diabetic nephropathy: a cohort study.
|
|
|
Vitamin D and subclinical cerebrovascular disease: the Atherosclerosis Risk in Communities brain magnetic resonance imaging study.
|
|
|
Vitamin D and cognitive function and dementia risk in a biracial cohort: the ARIC Brain MRI Study.
|
|
|
Comparison of two creatinine-based estimating equations in predicting all-cause and cardiovascular mortality in patients with type 2 diabetes.
|
|
|
Comparative performance of four equations estimating glomerular filtration rate in adult Chinese diabetics.
|
|
|
Glomerular filtration rate is associated with burden of coronary atherosclerosis in patients with acute coronary syndrome.
|
|
|
Comparison of the MDRD Study and the CKD-EPI Study equations in evaluating trends of estimated kidney function at population level: findings from the National FINRISK Study.
|
|
|
Evaluation of Chronic Kidney Disease Epidemiology Collaboration equation to estimate glomerular filtration rate in scleroderma patients. |
|




























